Company intelligence / Profile preview

Fresh2 Group

New York, New York, United States

Ownership: Public · FRES
Employees: ~75
Development stage: Other

Overview

Fresh2 Group has developed and commercialized multi-cancer screening and detection tests using its proprietary CDA technology. The company operates certified clinical laboratories in China and a CLIA/CAP-accredited lab in the US. It offers a suite of cancer screening tests to corporations and life insurance companies, as well as physical checkup packages. No clinical trial results for therapeutics are reported; the focus is on diagnostic commercialization[1][2].

Therapeutic areas: Oncology
Modalities: Diagnostic deviceGenomics testImmunological testBio-chemical test
Industry: Molecular Diagnostics

Financials

Market cap: $2.1M
Total revenue: $4.5M
Enterprise value: $-1.2M

Beyond the preview

Go deeper on Fresh2 Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fresh2 Group.

Explore the full profile